| Q56506042 | 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative |
| Q34130671 | 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative |
| Q38782336 | 2016 update of the EULAR recommendations for the management of early arthritis |
| Q47208181 | 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis |
| Q46930972 | A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis |
| Q42293325 | A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients |
| Q47755963 | A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis |
| Q40430356 | A case of Erdheim-Chester disease initially mistaken for Ormond's disease |
| Q38389487 | A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome |
| Q27309258 | A prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis |
| Q40327635 | A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis |
| Q37465508 | A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumato |
| Q43050554 | A unique autoantibody pattern of positive anti-Jo-1, anti-U1RNP, and antiproteasome antibodies in autoimmune myositis as a diagnostic challenge |
| Q33782402 | Access to disease modifying treatments for rheumatoid arthritis patients |
| Q72386255 | Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro |
| Q34587471 | Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation |
| Q35953319 | Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial |
| Q37616969 | Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis |
| Q37404893 | Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases |
| Q52907539 | Adaptation of human CD4+ T cells to pathophysiological hypoxia: a transcriptome analysis. |
| Q37977672 | Adaptive immunity in rheumatic diseases: bystander or pathogenic player? |
| Q72221440 | Advances in immunotherapy of rheumatoid arthritis: clinical and immunological findings following treatment with anti-CD4 antibodies |
| Q38007924 | After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? |
| Q38028464 | After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? |
| Q39257281 | An anti-CD4 antibody for treatment of chronic inflammatory arthritis. |
| Q36772881 | An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status |
| Q36681791 | Analysis of distribution and severity of inflammation in patients with osteoarthitis compared to rheumatoid arthritis by ICG-enhanced fluorescence optical imaging and musculoskeletal ultrasound: a pilot study |
| Q24800884 | Analysis of immunoglobulin light chain rearrangements in the salivary gland and blood of a patient with Sjögren's syndrome |
| Q69842980 | Analysis of leukemic cells with monoclonal antibodies in acute myelomonocytic leukemia suggests abnormality at an early differentiation stage in certain cases |
| Q33765684 | Angiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients |
| Q53007404 | Anti-52 kDa Ro(SSA) autoantibodies in different autoimmune diseases preferentially recognize epitopes on the central region of the antigen. |
| Q35620345 | Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus |
| Q48162893 | Anti-interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis |
| Q52979605 | Anti-phospholipid antibodies and CD5+ B cells in HIV infection. |
| Q37207105 | Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients |
| Q37433729 | Anticytokine therapy impacting on B cells in autoimmune diseases |
| Q41692630 | Antigenicity and accessory cell function of human articular chondrocytes |
| Q38046009 | Antiphospholipid antibody profiling: time for a new technical approach? |
| Q47875729 | Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study |
| Q73137037 | Artificial tissues in perfusion culture |
| Q64111757 | Association between baseline clinical and imaging findings and the development of digital ulcers in patients with systemic sclerosis |
| Q42639324 | Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis |
| Q37689681 | Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis |
| Q24792552 | Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells |
| Q41485269 | Automated evaluation of ANA under real-life conditions |
| Q33923278 | Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests |
| Q36851881 | Autoregulation of Th1-mediated inflammation by twist1. |
| Q37542901 | B-cell-directed therapies for autoimmune disease |
| Q44700348 | BMP2 initiates chondrogenic lineage development of adult human mesenchymal stem cells in high-density culture |
| Q40539566 | Basic mechanisms in rheumatoid arthritis: the role of T lymphocytes in rheumatoid synovitis |
| Q73168904 | Beware of the heart: the multiple picture of cardiac involvement in myositis |
| Q71403610 | Biochemical characterization and microsequencing of a 205-kDa synovial protein stimulatory for T cells and reactive with rheumatoid factor containing sera |
| Q52968093 | Bioenergetics of human peripheral blood mononuclear cell metabolism in quiescent, activated, and glucocorticoid-treated states. |
| Q35552329 | Bioenergetics of immune cells to assess rheumatic disease activity and efficacy of glucocorticoid treatment |
| Q26780316 | Biologicals in rheumatoid arthritis: current and future |
| Q27021115 | Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement |
| Q42461815 | Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function |
| Q51622761 | Bone engineering on the basis of periosteal cells cultured in polymer fleeces. |
| Q37350899 | Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients |
| Q44173489 | CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation |
| Q34912934 | CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice |
| Q44389394 | Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases |
| Q36577448 | Can engineered cartilage transplants be used for treating rheumatic diseases? |
| Q36918405 | Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients |
| Q41146137 | Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis |
| Q36757060 | Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study |
| Q35552605 | Case Number 26: Systemic idiopathic fibrosis associated with aortitis |
| Q36465497 | Cells of the synovium in rheumatoid arthritis. Macrophages |
| Q41719183 | Cellular immune response toward human articular chondrocytes. T cell reactivities against chondrocyte and fibroblast membranes in destructive joint diseases |
| Q37604489 | Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III st |
| Q34905646 | Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial |
| Q70326711 | Changes in cell surface antigen expression on human articular chondrocytes induced by gamma-interferon. Induction of Ia antigens |
| Q52010014 | Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells. |
| Q52980619 | Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate mark |
| Q34580607 | Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma |
| Q28206786 | Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases |
| Q24546386 | Cis- and trans-acting gene regulation is associated with osteoarthritis |
| Q67916499 | Class II antigen induction in cartilage |
| Q52904796 | Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development. |
| Q59891527 | Clinical Responses and Improvements in Patient-Reported Outcomes are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol |
| Q34897423 | Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register |
| Q51201612 | Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). |
| Q42641063 | Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study |
| Q58668744 | Clinical trials: how to cope with medical needs, ethics and timelines |
| Q43051066 | Coincidence of asymptomatic avascular necrosis and fracture of the femoral neck: a rare combination of glucocorticoid induced side effects |
| Q52658677 | Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (RMDs) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (EULAR) and the Ameri |
| Q52662457 | Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the Americ |
| Q72924000 | Comparison of 99Tcm-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis |
| Q52863587 | Comparison of Photo Optical Imaging with Musculoskeletal Ultrasound and Clinical Examination in the Assessment of Inflammatory Activity in Proximal Interphalangeal Joints in Rheumatoid Arthritis and Osteoarthritis. |
| Q36815091 | Comparison of rheumatoid test procedures--value and critical interpretation of sensitivity and specificity and their effect on pre-test and post-test probability |
| Q36677277 | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| Q33954663 | Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis |
| Q35638676 | Consensus statement on the use of rituximab in patients with rheumatoid arthritis |
| Q51504932 | Contrast-enhanced ultrasonography is more sensitive than grayscale and power Doppler ultrasonography compared to MRI in therapy monitoring of rheumatoid arthritis patients. |
| Q53145028 | Contrast-enhanced ultrasound for the monitoring of the efficacy of intra-articular glucocorticosteroids in 2 patients with inflammatory knee joint synovitis. |
| Q46674813 | Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI. |
| Q45804598 | Correction: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus |
| Q47913418 | Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus |
| Q46484971 | Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy |
| Q37744356 | Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis |
| Q37954539 | Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report |
| Q44028062 | Cutaneous T cell lymphoma in a patient with primary biliary cirrhosis and secondary Sjögren's syndrome. |
| Q24684384 | Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis |
| Q36603266 | Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study |
| Q33635438 | Defining TNF-α- and LPS-induced gene signatures in monocytes to unravel the complexity of peripheral blood transcriptomes in health and disease |
| Q43527343 | Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system |
| Q56570654 | Design of a phase IV randomised, double-blind, placebo-controlled trial assessing the Imact of esidual Inflammation Detected via Imaging Tchniques, rug Levels and Patient Characteristics on the Outcome of Dose Taperng of Adalimumab in linical Remissi |
| Q37122482 | Detailed Joint Region Analysis of the 7-Joint Ultrasound Score: Evaluation of an Arthritis Patient Cohort over One Year |
| Q21195665 | Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study |
| Q35792008 | Detection of oncofetal h19 RNA in rheumatoid arthritis synovial tissue |
| Q38878435 | Detection of severe digital vasculopathy in systemic sclerosis by colour Doppler sonography is associated with digital ulcers |
| Q43824681 | Development and resolution of secondary autoimmunity after autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: competition of plasma cells for survival niches? |
| Q34051439 | Diagnostic importance of anti-proteasome antibodies |
| Q35760128 | Diagnostic quality and scoring of synovitis, tenosynovitis and erosions in low-field MRI of patients with rheumatoid arthritis: a comparison with conventional MRI |
| Q35620320 | Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus |
| Q37207137 | Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort |
| Q47685856 | Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain rea |
| Q24812278 | Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus |
| Q42125132 | Differential immunological response of patients with rheumatoid arthritis towards two different Epstein-Barr virus strains: inhibition of interleukin-1 release by the B95-8, but not the P3HR-1 virus strain |
| Q71821539 | Differential recognition of the 52-kd Ro(SS-A) antigen by sera from patients with primary biliary cirrhosis and primary Sjögren's syndrome |
| Q45750569 | Diffuse infiltrative lymphocytosis syndrome in a patient with anti-52-kd Ro/SSA and human immunodeficiency virus type 1. |
| Q48044670 | Disentangling the effects of tocilizumab on neutrophil survival and function |
| Q72804652 | Dissociation of helper/inducer T-cell functions: immunodeficiency associated with mycobacterial histiocytosis |
| Q33651547 | Disturbed microcirculation in the hands of patients with systemic sclerosis detected by fluorescence optical imaging: a pilot study |
| Q73163240 | Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus |
| Q47370643 | Do we still miss the chance of effectively treating early rheumatoid arthritis? New answers from a new study |
| Q27026582 | EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria |
| Q35896648 | EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis |
| Q34110066 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs |
| Q26859134 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update |
| Q40305889 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update |
| Q95592414 | EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update |
| Q35555075 | EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis |
| Q35555103 | EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: exploring decision rules for clinical utility |
| Q41949374 | EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees |
| Q46037354 | Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. |
| Q52896474 | Effect of biofeedback and deep oscillation on Raynaud's phenomenon secondary to systemic sclerosis: results of a controlled prospective randomized clinical trial. |
| Q55315590 | Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. |
| Q34758824 | Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). |
| Q35833605 | Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters |
| Q52914239 | Effects of Porphyromonas gingivalis on cell cycle progression and apoptosis of primary human chondrocytes. |
| Q42481349 | Effects of anti-CD4 antibodies on the release of IL-6 and TNF-alpha in whole blood samples from patients with systemic lupus erythematosus |
| Q43141462 | Effects of hypoxia and/or lack of glucose on cellular energy metabolism and cytokine production in stimulated human CD4+ T lymphocytes |
| Q71513323 | Effects of methylprednisolone and 21-aminosteroids on mitogen-induced interleukin-6 and tumor necrosis factor-alpha production in human peripheral blood mononuclear cells |
| Q47839671 | Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis |
| Q34533379 | Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate |
| Q39929401 | Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study |
| Q37172820 | Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial |
| Q34317197 | Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis |
| Q43855238 | Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). |
| Q40447501 | Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. |
| Q42090806 | Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA) |
| Q35552265 | Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study |
| Q39173480 | Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis |
| Q35637863 | Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial |
| Q67996980 | Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis |
| Q38161794 | Emerging cell and cytokine targets in rheumatoid arthritis |
| Q53006602 | Encapsulation of artificial tissues in polyelectrolyte complexes: preliminary studies. |
| Q50773036 | Engineering of cartilage tissue using bioresorbable polymer carriers in perfusion culture. |
| Q36671703 | Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNF alpha |
| Q52928524 | Enhanced mutational activity and disturbed selection of mutations in V(H) gene rearrangements in a patient with systemic lupus erythematosus. |
| Q40597145 | Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity |
| Q44632405 | Epidemiology and therapy of Lyme arthritis and other manifestations of Lyme borreliosis in Germany: results of a nation-wide survey |
| Q35605535 | Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study |
| Q38661777 | European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update |
| Q37939700 | European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies |
| Q34818608 | Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period |
| Q56962379 | Evaluation of a new erosion score by musculoskeletal ultrasound in patients with rheumatoid arthritis: is US ready for a new erosion score? |
| Q37710906 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search |
| Q38492012 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update |
| Q37799337 | Exogenous and endogenous glucocorticoids in rheumatic diseases |
| Q56770990 | Expanding possibilities in the treatment of patient groups with previously difficult-to-treat patients |
| Q43260560 | Expression of proteasomal immunosubunit beta1i is dysregulated in inflammatory infiltrates of minor salivary glands in Sjogren's syndrome |
| Q63859672 | Expression of the CD2 Activation Epitope T11-3 (CD2R) on T Cells in Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ankylosing Spondylitis, and Lyme Disease: Phenotypic and Functional Analysis |
| Q45738840 | Fatal atypical T-cell proliferation associated with Epstein-Barr virus infection |
| Q52890084 | Fibrinogen and factor XIII A-subunit genotypes interactively influence C-reactive protein levels during inflammation. |
| Q31105353 | First clinical evaluation of sagittal laser optical tomography for detection of synovitis in arthritic finger joints |
| Q53107015 | Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. |
| Q42518281 | Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus |
| Q34207090 | Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial |
| Q46728295 | From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases |
| Q70043654 | Functional and phenotypical characterization of activated T cells from intra-articular sites in inflammatory joint diseases. Possible modulation of the CD3 antigen |
| Q52884551 | Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome. |
| Q51245422 | Gene expression profiling of human articular cartilage grafts generated by tissue engineering. |
| Q38303453 | Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs |
| Q40603810 | Genomic stratification by expression of HLA-DRB4 alleles identifies differential innate and adaptive immune transcriptional patterns - A strategy to detect predictors of methotrexate response in early rheumatoid arthritis |
| Q38128726 | German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs |
| Q35941069 | Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action |
| Q44136305 | Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid |
| Q45069338 | Gonarthritis, lymphadenopathy and disseminated choroiditis as a primary manifestation of Lyme borreliosis. Case report and discussion of diagnostic possibilities in Lyme borreliosis |
| Q43048655 | Granulomatous synovialitis with erosions in the shoulder joint: a rare case of polyarthritis caused by Mycobacterium kansasii |
| Q35550646 | Guidelines for musculoskeletal ultrasound in rheumatology |
| Q39173670 | Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study |
| Q37846494 | Heparin or aspirin or both in the treatment of recurrent abortions in women with antiphospholipid antibody (syndrome). |
| Q38787551 | High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block |
| Q45027324 | High-sensitivity immunofluorescence staining: a comparison of the liposome procedure and the FASER technique on mGR detection |
| Q33591655 | Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus |
| Q70577417 | Human CD4 modulation in vivo induced by antibody treatment |
| Q46584245 | Human CD4(+) T cells maintain specific functions even under conditions of extremely restricted ATP production |
| Q70141209 | Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis |
| Q41884428 | Human anti-murine immunoglobulin antibodies as disturbing factors in TSH determination |
| Q37729352 | Human immune cells' behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma model |
| Q43241236 | Human monocytes and macrophages differ in their mechanisms of adaptation to hypoxia |
| Q70557839 | Human mononuclear phagocytes differentiation antigens |
| Q34446781 | Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial |
| Q36084438 | Hypoxia inducible factor (HIF) in rheumatology: low O2! See what HIF can do! |
| Q44911567 | IFNα and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus |
| Q69710811 | IGM-containing immune complexes and antiphospholipid antibodies in patients with Sneddon's syndrome |
| Q70561942 | Ia+ T cells in synovial fluid and tissues of patients with rheumatoid arthritis |
| Q40672471 | Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies |
| Q33180160 | Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis |
| Q70902289 | Identification of three major synovial lining cell populations by monoclonal antibodies directed to Ia antigens and antigens associated with monocytes/macrophages and fibroblasts |
| Q69894472 | IgE-containing circulating immune complexes in Churg-Strauss vasculitis |
| Q72374919 | Imaging rheumatoid arthritis joints with technetium-99m labelled specific anti-CD4- and non-specific monoclonal antibodies |
| Q68437609 | Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies |
| Q34027640 | Immediate determination of ACPA and rheumatoid factor--a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay |
| Q53004437 | Immunodominant autoepitopes. Mechanisms of autoantibody induction in autoimmune diseases?. |
| Q40832370 | Immunologic findings in homosexual males with generalized lymphadenopathy. Prodromal state of acquired immunodeficiency syndrome? |
| Q48355113 | Immunological characterization of the early human fracture hematoma |
| Q72839370 | Immunological characterization of unusual plasmacytic tumor cells in a disseminated non-Hodgkin's lymphoma |
| Q36489109 | Immunological memory stabilizing autoreactivity |
| Q71296747 | Immunological studies in homosexual men with unexplained lymphadenopathy |
| Q41722148 | Immunological treatment of autoimmune diseases. |
| Q54577583 | Immunologically restricted patients exhibit a pronounced inflammation and inadequate response to hypoxia in fracture hematomas. |
| Q36571741 | Immunopathologic role of B lymphocytes in rheumatoid arthritis: rationale of B cell-directed therapy |
| Q37012723 | Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial |
| Q54288738 | Impact of the CTLA-4/CD28 axis on the processes of joint inflammation in rheumatoid arthritis. |
| Q55396986 | Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. |
| Q39319086 | Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy |
| Q52820837 | Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, |
| Q36252760 | Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study |
| Q40774493 | Increased Periodontal Attachment Loss in Patients With Systemic Sclerosis |
| Q39039495 | Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics |
| Q43088759 | Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). |
| Q52968820 | Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. |
| Q46169259 | Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imaging |
| Q43003928 | Induced apoptosis of chondrocytes by Porphyromonas gingivalis as a possible pathway for cartilage loss in rheumatoid arthritis |
| Q72113351 | Induction of a lymphotoxin-like mediator in peripheral blood and synovial fluid lymphocytes by incubation with synovial fluid from patients with rheumatoid arthritis |
| Q51823390 | Induction of pathogenic anti-dsDNA antibodies is controlled on the level of B cells in a non-lupus prone mouse strain. |
| Q56334428 | Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial |
| Q45736528 | Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study |
| Q71668217 | Inexpensive computer analysis of cell and tissue stainings |
| Q38768740 | Inflammation Is an Important Covariate for the Crosstalk of Sleep and the HPA Axis in Rheumatoid Arthritis |
| Q35819019 | Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology |
| Q52914312 | Inflammation, glucocorticoids and risk of cardiovascular disease. |
| Q52617097 | Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases. |
| Q52917057 | Influence of peptidylarginine deiminase type 4 genotype and shared epitope on clinical characteristics and autoantibody profile of rheumatoid arthritis. |
| Q42595183 | Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy |
| Q34897437 | Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus |
| Q70142686 | Intraarticular T lymphocytes in monoarticular and oligoarticular inflammatory joint diseases. Normal subset distribution and less numbers of activated T cells indicate major differences as compared to rheumatoid arthritis |
| Q70321937 | Intralymphatic interleukin 2 treatment in patients with acquired immunodeficiency syndrome: preliminary experience in three cases |
| Q45888906 | Intralymphatic interleukin-2 treatment of a hemophiliac AIDS patient with defective interleukin-2 production |
| Q36183828 | Introducing RMD Open |
| Q52900457 | Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. |
| Q67901148 | Kinetics of 99mTc-labelled antibodies against CD4 (T-helper) lymphocytes in man |
| Q42640325 | Kitasato Symposium 2010: new prospects for cytokines |
| Q42544274 | Kitasato symposium 2009: new prospects for cytokine inhibition |
| Q39910186 | Knee osteoarthritis. Efficacy of a new method of contrast-enhanced musculoskeletal ultrasonography in detection of synovitis in patients with knee osteoarthritis in comparison with magnetic resonance imaging |
| Q31119751 | Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction |
| Q48023919 | Long-term follow-up of fertility and pregnancy in autoimmune diseases after autologous haematopoietic stem cell transplantation |
| Q39070608 | Low immunogenicity of tocilizumab in patients with rheumatoid arthritis |
| Q39853662 | Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study |
| Q50940528 | Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. |
| Q52899745 | Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia. |
| Q35838765 | Management of early inflammatory arthritis. Intervention with immunomodulatory agents: monoclonal antibody therapy |
| Q38670973 | Managing rheumatic and musculoskeletal diseases - past, present and future |
| Q38810115 | Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4+ and CD8+ T cells and macrophages |
| Q50110839 | Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis |
| Q34187345 | Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study |
| Q52930641 | Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis. |
| Q52947235 | Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. |
| Q40567085 | Modulation of intracellular calcium signaling and mitochondrial function in cultured osteoblastic cells by dexamethasone and celecoxib during mechanical stimulation. |
| Q71617653 | Monoclonal antibodies against human chondrocytes |
| Q47162376 | Monocytes and Macrophages in Synovitis: Villains or Victims? |
| Q35549230 | Monocytes from systemic lupus erythematous patients are severely altered in phenotype and lineage flexibility |
| Q41329447 | Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? |
| Q37723128 | More night than day--circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis |
| Q34658023 | Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab |
| Q72778195 | Multiple abnormalities in immunoregulatory function of synovial compartment T cells in patients with rheumatoid arthritis. Recognition of a helper augmentation effect |
| Q24793730 | Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases |
| Q28238667 | Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis |
| Q42410302 | N-terminal prohormone brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with rheumatoid arthritis or osteoarthritis? |
| Q52867119 | Near-infrared Fluorescence Optical Imaging in Early Rheumatoid Arthritis: A Comparison to Magnetic Resonance Imaging and Ultrasonography. |
| Q37128305 | New approaches of B-cell-directed therapy: beyond rituximab |
| Q36183809 | Non-surgical management of knee osteoarthritis: where are we now and where do we need to go? |
| Q44441116 | Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells |
| Q44095136 | Norepinephrine inhibits energy metabolism of human peripheral blood mononuclear cells via adrenergic receptors |
| Q41155224 | Novel autoantibodies against muscle-cell membrane proteins in patients with myositis |
| Q73092737 | Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus |
| Q42472223 | Nutritional status as marker for disease activity and severity predicting mortality in patients with systemic sclerosis |
| Q56963263 | Observational study and brief analysis of diagnostic criteria in relapsing polychondritis |
| Q57808902 | On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis |
| Q36055764 | Optimised glucocorticoid therapy: the sharpening of an old spear |
| Q44213178 | Origin and functional activity of the membrane-bound glucocorticoid receptor |
| Q42035666 | Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes |
| Q44973377 | Pathophysiological hypoxia affects the redox state and IL-2 signalling of human CD4+ T cells and concomitantly impairs survival and proliferation |
| Q55360477 | Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. |
| Q52905385 | Patient-tailored therapy in rheumatoid arthritis: an editorial review. |
| Q35249630 | Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria |
| Q72607871 | Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis |
| Q44600387 | Persistent depletion of CD4+ T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy |
| Q41280714 | Persistent pulmonary lesion in a patient with rheumatoid arthritis |
| Q24805489 | Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategies |
| Q42146734 | Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA. |
| Q37702631 | Pharmacology of glucocorticoids in rheumatoid arthritis |
| Q52958543 | Porcine mesenchymal stem cells. Induction of distinct mesenchymal cell lineages. |
| Q46847017 | Potencies of topical glucocorticoids to mediate genomic and nongenomic effects on human peripheral blood mononuclear cells |
| Q37948243 | Prednisone chronotherapy |
| Q64891130 | Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. |
| Q46060391 | Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans |
| Q72822501 | Preservation of the helper and suppressor/cytotoxic T-lymphocyte phenotype in continuous culture |
| Q45011194 | Prevalence of 20S proteasome, anti-nuclear and thyroid antibodies in young patients at onset of type 1 diabetes mellitus and the risk of autoimmune thyroiditis |
| Q35728708 | Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study |
| Q43945134 | Progressive multifocal leukoencephalopathy in a patient with undifferentiated systemic vasculitis and bilateral acute retinal necrosis |
| Q35550164 | Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls |
| Q30489871 | Prospective 7 year follow up imaging study comparing radiography, ultrasonography, and magnetic resonance imaging in rheumatoid arthritis finger joints |
| Q30500517 | Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints |
| Q46668525 | Prostaglandin E2, interleukin 1 and gamma interferon production of mononuclear cells of patients with inflammatory and degenerative joint diseases |
| Q42943799 | Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus |
| Q42953257 | Prothrombin 20210G>A genotype and C-reactive protein level |
| Q40377000 | ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany |
| Q55501133 | Rapid Typing of Borrelia burgdorferi Sensu Lato Species in Specimens from Patients with Different Manifestations of Lyme Borreliosis. |
| Q34413310 | Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized cont |
| Q52870411 | Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. |
| Q64293304 | Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study |
| Q37501529 | Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study |
| Q72069143 | Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis |
| Q51578843 | Regenerative medicine in rheumatic disease-progress in tissue engineering. |
| Q72731767 | Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin 1, downregulation by transforming growth factor beta and upregulation by fibrobl |
| Q53097441 | Reliability of the novel 7-joint ultrasound score: results from an inter- and intraobserver study performed by rheumatologists. |
| Q33365103 | Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries |
| Q44611084 | Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients |
| Q52876330 | Response to H Zeidler's comments on the CONCERTO study. |
| Q52814849 | Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers. |
| Q35744377 | Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis |
| Q52850188 | Rheumatoid arthritis: Glucocorticoid therapy and body composition. |
| Q35753685 | Rheumatoid factor revisited |
| Q72840529 | Rheumatoid non-lymphoid synovial cells and the induction of mixed leukocyte reactions. Low-density preparations containing Ia+ macrophages and dendritic cells are less stimulatory than peripheral blood non-T cells |
| Q43110492 | Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells |
| Q44774931 | Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks |
| Q33765608 | Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients |
| Q53487037 | Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. |
| Q45123594 | Role of cytokines and growth factors in joint destruction processes |
| Q37587370 | SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome |
| Q35637322 | Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis |
| Q37691205 | Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study |
| Q36394613 | Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2) |
| Q39180660 | Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis |
| Q39176539 | Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors |
| Q45242440 | Segmental bone repair by tissue-engineered periosteal cell transplants with bioresorbable fleece and fibrin scaffolds in rabbits |
| Q37330991 | Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis |
| Q37521446 | Severe disease activity and complications of immunosuppressive therapy: a challenge for acute hospital-based rehabilitation in rheumatology |
| Q34517056 | Short-term effects of the 21-aminosteroid lazaroid tirilazad mesylate (PNU-74006F) and the pyrrolopyrimidine lazaroid PNU-101033E on energy metabolism of human peripheral blood mononuclear cells |
| Q33959460 | Shwartzman phenomenon in a patient with active systemic lupus erythematosus preceding fatal disseminated intravascular coagulation |
| Q33415370 | SiPaGene: A new repository for instant online retrieval, sharing and meta-analyses of GeneChip expression data |
| Q35617645 | Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay |
| Q27477929 | Sinusoidal dilatation: a rare side effect of azathioprine |
| Q38078921 | Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis |
| Q41471156 | Specific drugs for a complex disease: can there be a magic bullet against rheumatoid arthritis? |
| Q33403170 | Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia |
| Q35551818 | Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology |
| Q52954445 | Stem cells for regenerative medicine: advances in the engineering of tissues and organs. |
| Q70241390 | Stimulation of rheumatoid synovial and blood T cells and lines by synovial fluid and interleukin-2: characterization of clones and recognition of a co-stimulatory effect |
| Q52100688 | Stimulatory response towards the 65 kDa heat shock protein and other mycobacterial antigens in patients with rheumatoid arthritis. |
| Q35952053 | Strategies using functional genomics in rheumatic diseases |
| Q43048599 | Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist |
| Q45780400 | Surface CD152 (CTLA-4) expression and signaling dictates longevity of CD28null T cells |
| Q36081613 | Sustained Increase of 25-Hydroxyvitamin D Levels in Healthy Young Women during Wintertime after Three Suberythemal UV Irradiations-The MUVY Pilot Study |
| Q42376818 | Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis |
| Q67921687 | Synovial fluid involvement in null cell acute lymphoblastic leukemia diagnosed with monoclonal antibodies |
| Q70134663 | T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation |
| Q43050965 | T cell reactivity against the SmD1(83-119) C terminal peptide in patients with systemic lupus erythematosus |
| Q52892758 | Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. |
| Q28067377 | Targeting GM-CSF in rheumatoid arthritis |
| Q44657885 | Tenosynovitis of the flexor tendons of the hand detected by MRI: an early indicator of rheumatoid arthritis |
| Q34802740 | The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report |
| Q42955715 | The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year |
| Q30453312 | The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy |
| Q36245707 | The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression |
| Q34346150 | The association between rheumatoid arthritis and periodontal disease |
| Q35545690 | The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers |
| Q26766515 | The changing landscape of biosimilars in rheumatology |
| Q35533763 | The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal Diseases |
| Q43550455 | The immunologic homunculus in rheumatoid arthritis. A new viewpoint of immunopathogenesis in rheumatoid arthritis and therapeutic consequences |
| Q52890123 | The impact of Porphyromonas gingivalis lipids on apoptosis of primary human chondrocytes. |
| Q28368414 | The p68 autoantigen characteristic of rheumatoid arthritis is reactive with carbohydrate epitope specific autoantibodies |
| Q51604946 | The proteasome - victim or culprit in autoimmunity. |
| Q34464260 | The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus |
| Q35111838 | The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets |
| Q68044861 | The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis |
| Q38068691 | The role of biosimilars in the treatment of rheumatic diseases |
| Q44373466 | The role of cytokines and growth factors in rheumatoid joint destruction |
| Q24646963 | The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens |
| Q51980568 | The systemic and SmD183-119-autoantigen-specific cytokine memory of Th cells in SLE patients. |
| Q70328576 | The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens |
| Q70365326 | The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. II. The localization of mononuclear cells as detected by monoclonal antibodies directed against T-lymphocyte subsets and natural killer cells |
| Q38368847 | The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. |
| Q27007783 | The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016 |
| Q52974074 | Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. |
| Q46485350 | Three joints swollen, blood sedimentation increased. Methotrexate to be given immediately? |
| Q52969700 | Tissue engineered cartilage repair using cryopreserved and noncryopreserved chondrocytes. |
| Q52976797 | Tissue engineering of biphasic joint cartilage transplants. |
| Q41146132 | Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial |
| Q36968747 | Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial |
| Q45842857 | Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial |
| Q44818742 | Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial |
| Q55461410 | Toll-like receptor dependent autoantigens in animal models and humans in use to improve collagen induced arthritis. |
| Q69979560 | Total lymphoid irradiation in patients with refractory rheumatoid arthritis |
| Q51066523 | Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. |
| Q59616273 | Translational prospects for cytokines in 2011. Abstracts of the Kitasato Symposium 2011. Potsdam, Germany. September 22-23, 2011 |
| Q35740447 | Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire |
| Q38476881 | Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force |
| Q34462557 | Treating rheumatoid arthritis to target: recommendations of an international task force |
| Q41687116 | Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab |
| Q73208716 | Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin |
| Q41091262 | Treatment of autoimmune diseases and graft rejection with anti-CD4 antibodies |
| Q35869048 | Treatment of posttraumatic and focal osteoarthritic cartilage defects of the knee with autologous polymer-based three-dimensional chondrocyte grafts: 2-year clinical results |
| Q40752113 | Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody |
| Q51115405 | Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). |
| Q47119014 | Type 1 regulatory T cells in treatment of murine lupus. |
| Q38867891 | Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options |
| Q57146825 | Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis |
| Q43500939 | Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus |
| Q91318833 | Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018 |
| Q90990134 | Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019 |
| Q35638252 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. |
| Q36171750 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 |
| Q37331061 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. |
| Q37649029 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. |
| Q37845564 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. |
| Q37998319 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. |
| Q38093452 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. |
| Q35579352 | Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. |
| Q35579517 | Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 |
| Q27691388 | Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis |
| Q34071238 | Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000) |
| Q34560553 | Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001) |
| Q34010999 | Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNΓ |
| Q39454337 | Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response |
| Q47831840 | Usefulness of power Doppler ultrasound for prediction of re-therapy with rituximab in rheumatoid arthritis: a prospective study of longstanding rheumatoid arthritis patients |
| Q52997075 | Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases. |
| Q38915319 | What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. |
| Q43049535 | Which dose regimen for glucocorticoid pulse therapy in patients with severe refractory RA? |
| Q58816401 | Wirkungsmechanismen der hochdosierten Glucocorticoidtherapie |
| Q71627105 | [Clinical aspects and diagnosis of systemic lupus erythematosus] |
| Q52207585 | [Combination of rare anomalies of the cervical spine and peripheral skeleton] |
| Q52925620 | [Disease-modifying effects of glucocorticoids in rheumatoid arthritis]. |
| Q52923647 | [Gene expression in inflammatory rheumatic diseases] |
| Q52903646 | [Guidelines--a long road to clinical application]. |
| Q70732036 | [High-dose immunoglobulin therapy of rheumatoid arthritis] |
| Q52994708 | [Iloprost administration over 21 days as an effective therapy in systemic scleroderma--case report and review of the literature] |
| Q52948664 | [Imaging techniques in rheumatology: scintigraphy in rheumatoid arthritis] |
| Q71698531 | [Immunomodulating therapy of rheumatoid arthritis (chronic polyarthritis): use of monoclonal antibodies] |
| Q52875330 | [Interface between university medicine and patient care]. |
| Q73081488 | [Mechanism of action of gold in treatment of rheumatoid arthritis] |
| Q52974448 | [Protection of autogenous cartilage transplants from resorption using membrane encapsulation] |
| Q50511647 | [Protracted course of polychondritis as the etiology of progressive nose deformity, subglottic tracheal stenosis and inner ear hearing loss] |
| Q52979607 | [Reactive arthritis. Diagnosis, differential diagnosis and therapy] |
| Q52937753 | [Rheumatology]. |
| Q52852823 | [Standards of care for people with rheumatoid arthritis in Europe : Translation and comments of the eumusc.net recommendations supported by EULAR performed by a national task force of the professional organisations DGRh and VRA supported by "Deutsch |
| Q71207485 | [Successful therapeutic management of risk pregnancy in primary Sjögren syndrome with plasmapheresis and dexamethasone] |
| Q67695292 | [Suppression of monocyte-macrophage activation by anti-CD4 therapy in patients with chronic polyarthritis] |
| Q52997732 | [The therapeutic potential of lazaroids (21-aminosteroids). A recent survey]. |
| Q53004852 | [The therapy of systemic lupus erythematosus] |
| Q53004099 | [Tissue engineering of human cartilage tissue for reconstructive surgery using biocompatible resorbable fibrin gel and polymer carriers] |
| Q52948018 | [Tissue engineering: chances and challenges for application in rheumatic diseases] |
| Q52850371 | [Treat to target and personalized medicine (precision medicine)]. |
| Q50518899 | p205 is a major target of autoreactive T cells in rheumatoid arthritis. |